Patients who participated in an investigator-initiated phase II study in pleurodesis for secondary intractable pneumothorax with sterile graded talc (protocol number: J-TALC2) with absence of chest tube removal within 30 days after pleurodesis, and who still have been hospitalized.
Conditions
Interventions
Intervention type:DRUG
Name of intervention:NO
Dose form / Japanese Medical Device Nomenclature:
Route of administration / Site of application:NOT APPLICABLE
Dose per administration:
Dosing frequency
Sponsors
National Hospital Organization Nagoya Medical Center Hideo Saka
Kyorin University Hospital, Teikyo University Hospital, Nihon University Itabashi Hospital, St. Marianna University School of Medicine, Nagoya Medical Center, Nagoya City University Hospital, Japanese Red Cross Okayama Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Participants in the investigator-initiated phase II study in pleurodesis for secondary intractable pneumothorax with sterile graded talc (protocol number: J-TALC2). (2)Patients who provided written consents for this study by themselves.
Exclusion criteria
Exclusion criteria: (1)Patients who were discharged during the observation period of J-TALC2 clinical trial. (2)Patients who discontinued participation during J-TALC2 trial period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (1)Presence or absence of discharge (discharge date in the case of presence, reason for discharge). (2)Presence or absence of chest tube removal. (3)Presence or absence of continuous treatment for pneumothorax. (4)Other (death, etc.). | — |
Countries
Japan
Contacts
Public ContactYutaka Ito
National Hospital Organization Nagoya Medical Center
Outcome results
None listed